---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-020510"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:02:07.344675+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting

## Summary
- Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).
- Shareholders approved amendment to 2022 Incentive Plan removing full-value award limit (66.7M for, 8.6M against).
- Two director nominees (Yann Echelard, Daniel Hume) each received less than 50% of votes cast for election.
- Advisory say-on-pay proposal passed with 55.6% support (42.3M for, 31.0M against).

## SEC filing metadata
- accession: 0001437749-24-020510
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 5.07, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774924020510/0001437749-24-020510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774924020510/tgtx20240614_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-020510
- JSON: https://secwatch.observer/filing/0001437749-24-020510.json
- Plain text: https://secwatch.observer/filing/0001437749-24-020510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.